✦ LIBER ✦

PMS7 COST ANALYSIS OF RECENTLY APPROVED AND OLDER ANTI-TNF BIOLOGIC AGENTS USED IN RHEUMATOID ARTHRITIS

✍ Scribed by C Carter; C Schmeichel-Mueller; RS McKenzie; CT Piech

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS51 A Cost Utility Analysis of Anti-TN

✍ R.C. Adams; C. Walsh; S. Schmitz; P. Barton; M. Barry 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

PMS8 Cost-Effectiveness analysis of Etan

✍ Lutz, M.; Cuesta, G.; Morales, G. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

PMS17 Cost Minimization of Anti-TNF Biol

✍ A.D. Morais; M.L. Pereira 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Cost-effectiveness modeling of abatacept

✍ Anthony Russell; Ariel Beresniak; Louis Bessette; Boulos Haraoui; Proton Rahman; 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 183 KB

PAR24 COST-UTILITY ANALYSIS OF RITUXIMAB

✍ V Brodszky; M Péntek; K Karpati; I Boncz; A Sebestyén; L Gulácsi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

PMS78 Analyzing the Difference in Health

✍ O. Baser; C. Schmeichel-mueller; M. Ingham 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB